Last update: October 19th 2014
October 16th 2014

EMA’s final policy on access to clinical data:...

On 2 October 2014, the European Medicines Agency (EMA) finally adopted its policy on access to clinical data. From 1 January 2015 onwards, the general public will be able to “view on screen” selected parts of trial reports submitted in support of marketing authorisations, and...

September 23th 2014

New EU Clinical Trials Regulation: a major...

Joint briefing paper by 7 organisations. The major advance in transparency brought by the adoption of the EU regulation on clinical trials needs to be preserved from neutralisation by industry lobbies.

September 19th 2014

INNs of biologics and biosimilars: consistency...

Joint response by HAI, ISDB and MiEF to a WHO public consultation. The WHO proposal to assign a "biological qualifier" after the International Nonproprietary Name (INN) of glycosylated biosimilars offers an acceptable...

September 16th 2014

A step backwards on pharmaceutical policy at...

Joint open letter to President Juncker by 28 organisations. Promoting profit over public health puts European citizens at risk. No, medicinal products are not just a commodity like any other.

for members only

NEWSLETTER

2014

March 03th 2014

March


ISDB Publications

Manuals & booklets

October 01th 2008

ISDB Booklet

ISDB Information Booklet
Independence from drug companies is a key element of our policy

booklet october 2008 english (639 KB) - spanish (624 KB)

ISDB - International Society of Drug bullettins

Contact details:
President: president@isdbweb.org
Webmaster: maria.font@ulss20.verona.it

© 2014